NASDAQ:PTEPolarityte Stock Price, Forecast & News

Polarityte's stock was trading at $1.07 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PTE shares have increased by 15.9% and is now trading at $1.24. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Polarityte in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Polarityte.

Polarityte Inc (NASDAQ:PTE) issued its quarterly earnings data on Monday, May, 11th. The company reported ($0.39) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.57) by $0.18. The company had revenue of $0.93 million for the quarter, compared to analysts' expectations of $1.27 million. Polarityte had a negative net margin of 1,561.72% and a negative return on equity of 157.30%. During the same period in the previous year, the firm earned ($1.18) earnings per share. View Polarityte's earnings history.

5 equities research analysts have issued 12-month price objectives for Polarityte's shares. Their forecasts range from $3.00 to $8.00. On average, they anticipate Polarityte's share price to reach $5.40 in the next year. This suggests a possible upside of 335.5% from the stock's current price. View analysts' price targets for Polarityte.

News articles about PTE stock have been trending negative recently, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Polarityte earned a media sentiment score of -2.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news about Polarityte.

Some companies that are related to Polarityte include Axcella Health (AXLA), Sutro Biopharma (STRO), Surface Oncology (SURF), Applied Genetic Technologies (AGTC), Verona Pharma (TARA), Cidara Therapeutics (CDTX), X4 Pharmaceuticals (XFOR), Erytech Pharma (ERYP), Solid Biosciences (SLDB), Ayala Pharmaceuticals (AYLA), La Jolla Pharmaceutical (LJPC), Outlook Therapeutics (OTLK), Champions Oncology (CSBR), Gamida Cell (GMDA) and Windtree Therapeutics (WINT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Polarityte investors own include Amplify Energy (AMPY), Amplify Energy (AMPY), Outlook Therapeutics (OTLK), Unum Therapeutics (UMRX), BioNano Genomics (BNGO), Seanergy Maritime (SHIP), Ekso Bionics (EKSO), Matinas BioPharma (MTNB), OrganiGram (OGI) and Titan Pharmaceuticals (TTNP).

Polarityte trades on the NASDAQ under the ticker symbol "PTE."

Shares of PTE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PTE stock can currently be purchased for approximately $1.24.

Polarityte has a market capitalization of $47.70 million and generates $5.65 million in revenue each year. The company earns $-92,490,000.00 in net income (profit) each year or ($3.70) on an earnings per share basis. Polarityte employs 153 workers across the globe.

The official website for Polarityte is www.polarityte.com.

Polarityte's mailing address is 123 NORTH WRIGHT BROTHERS DRIVE, SALT LAKE CITY UT, 84116. The company can be reached via phone at 385-237-2279 or via email at [email protected]